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Representative H/E staining of lung sections were shown in sham group (a), I/R induced ALI (b), rhMG53 administered 30 min prior to ischemia (precondition) (c), rhMG53 administered immediately after ischemia (treatment) (d), or rhMG53 administered 0.5 hour after reperfusion (0.5h treatment) (e). Scale bar = 100 µm. B. Histopathological assessments were conducted in a blinded fashion using the grading criteria listed in Table 2 . Statistical analyses showed that rhMG53 administration under the three different conditions all led to improvement of pathological changes of ALI (*P<0.05 vs. others, ANOVA, mean ± SEM). Effect of rhMG53 administration on mg53-/-mice. A. Survival rate of mg53-/-mice and mg53-/-mice treated with rhMG53 was recorded after I/R. The product limit (Kaplan-Meier) estimate of the cumulative survival was assessed with the log-rank test to evaluate for significant differences in survival (*P<0.05 vs. rhMG53 untreated mice; n=19 for mg53-/-mice and n=9 for mg53-/-mice treated with rhMG53). B. Lung edema was measured as the wet/dry weight ratio of the excised lung tissue from mice (*P<0.05 vs. rhMG53 untreated mice, n=5 in each group, ANOVA, mean ± SEM). C. Arterial blood samples were drawn from individual mice, the plasma PaO2 concentrations were measured (*P<0.05 vs. rhMG53 untreated , n=6 in each group, ANOVA, mean ± SEM). 
Survival (%) Time after I/R (min)
Supplementary Table 1 . Primers used for RACE analysis of mg53 in lung. A total of 16 randomly selected clones from 5' RACE product were sequenced. 11 clones were confirmed to start from 5' untranslated region with the complete same coding sequence of MG53 from muscle tissues. The other 5 clones started way into the coding region of muscle MG53, at the 27 th a.a., the 44 th a.a. ~, the 44 th a.a. ~, the 52 nd a.a. ~ and 58 th a.a.. Two independent 3' RACE clones were also sequenced and they had the same coding sequence of MG53 from muscle tissues. 
